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Summary 
Oxidative stress (OS) is an important contributing factor to male infertility. While previous 
methods to measure seminal OS are time-consuming and limited to the use of freshly 
produced semen, oxidation reduction potential (ORP) is easier and quicker to perform and 
can also be used in frozen semen. Therefore, this study evaluated the clinical utility of ORP as 
a potential marker of male infertility. ORP was measured in semen samples from 293 
patients and 15 fertile controls and categorised according to WHO criteria as 
normozoospermic, oligozoospermic, asthenozoospermic, teratozoospermic and 
oligoasthenoteratozoospermic. Receiver operating characteristic (ROC) curves were 
generated to differentiate these categories. Semen parameters were significantly different 
when subjects were grouped as control and patients or between the patient and 
normozoospermic group for concentration and morphology. ORP levels were significantly 
different between the control and normozoospermic group. When subjects were grouped 
based on concentration, motility, morphology or a combination of these, the area under the 
ROC curve, sensitivity, specificity, positive predictive value and cut-off values were 
significantly different. These differences were significant when combined with ORP and 
grouped with any two sperm abnormalities. In conclusion, ORP is a quick, easy, cost-
effective and reliable marker of semen quality as well as oxidative stress for use in a clinical 
setting. 
 
1  |  INTRODUCTION 
Male infertility affects up to 12% of men globally (Agarwal, Ahmad, & Sharma, 2015). Despite the 
ongoing controversies regarding the accuracy and predictive power of routine semen analysis, it 
continues to be used by many clinicians worldwide as a surrogate measure of a man’s ability to 
father a child (Esteves, 2010). The American Urological Association (AUA) has proposed the 
inclusion of advanced tests of sperm function as complementary methods that can enhance the 
diagnostic accuracy of male infertility particularly in cases of unexplained infertility, one or more 
abnormal semen parameters, recurrent pregnancy loss or failure of intrauterine insemination (AUA, 
2010). 
 
Oxidative stress (OS) occurs when the oxidants overwhelm the ability of the available 
antioxidants to scavenge the increase in the production of reactive oxygen species (ROS); OS is a 
2 
 
major contributor to male infertility. High levels of ROS are found in 25%–40% of infertile men 
and in 40%–80% of infertile patients with spinal cord injury (de Lamirande, Leduc, Iwasaki, 
Hassouna, & Gagnon, 1995; Sharma & Agarwal, 1996). In addition, infertile patients also have low 
levels of antioxidants in their seminal plasma (Ko, Sabanegh, & Agarwal, 2014; Roychoudhury, 
Sharma, Sikka, & Agarwal, 2016; Sharma, Pasqualotto, Nelson, Thomas, & Agarwal, 1999). Yet, for 
successful fertilisation, a balance between oxidants and available antioxidants is essential for 
normal chromatin compaction in maturing spermatozoa during epididymal transit, capacitation, 
hyperactivation, acrosome reaction and sperm–oocyte fusion (Henkel et al., 2005; Ko et al., 2014; 
Sharma & Agarwal, 1996). 
 
Accurate assessment of OS can be important for the clinical diagnosis and management of 
male infertility, especially in those with unexplained and idiopathic infertility. However, 
currently available assays for OS are tedious and employ costly equipment and skills as well 
as large sample volumes. Furthermore, they measure only a known or a discrete quantity of 
oxidants (ROS by chemiluminescence assay), antioxidants (total antioxidant capacity [TAC] 
assay) or post hoc damage (MDA assay, sperm DNA fragmentation) (Agarwal et al., 2015; 
Henkel et al., 2005; Ko et al., 2014; Moazamian et al., 2015; Roychoudhury et al., 2016; 
Sharma & Agarwal, 1996). 
 
Oxidation–reduction potential or ORP is a direct measurement of oxidative stress and 
therefore the redox imbalance between oxidants and antioxidants in biological samples. It is 
an integrated measure of the balance between total oxidants (i.e., oxidised thiols, superoxide 
radicals, hydroxyl radicals, hydrogen peroxide, nitric oxide, peroxynitrite and transition metal 
ions) and total reductants (i.e., free thiols, ascorbate, α-tocopherol, β-carotene and uric acid) 
(Agarwal, Sharma, Roychoudhury, du Plessis, & Sabanegh, 2016; Agarwal et al., 2017). 
 
ORP has been measured in a variety of biological specimens, including whole blood, serum, 
plasma and urine. As an indicator of oxidative stress, it has been shown to correlate well with 
illness and injury severity in trauma patients. For male infertility diagnostics, ORP represents 
a novel parameter that can be easily measured in fresh semen and seminal plasma up to 2 hr 
after production, as well as in frozen samples with the MiOXSYS system (Agarwal, Sharma 
et al., 2016). Reference values of ORP have been established in infertile men and healthy 
men of proven and unproven fertility, and higher ORP measures are associated with a 
decrease in sperm concentration and motility. Using this parameter, we were able to identify 
oxidative stress as a possible factor in male infertility (Agarwal, Gupta, & Sharma, 2016; 
Agarwal, Sharma et al., 2016; Agarwal et al., 2017). 
 
As ORP may have a clinical utility as a potential marker of semen parameters, the objective of 
this study was to compare 1) semen parameters and ORP in normozoospermic men versus 
oligozoospermic, asthenozoospermic, teratozoospermic and oligoasthenoteratozoospermic 
men; 2) establish the cut-off value, sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for semen parameters and ORP for these groups and 3) 




subjects with two semen abnormalities to see whether ORP can serve as a single clinical 
marker of male infertility. 
 
2  |  MATERIALS AND METHODS 
2.1  |  Subjects 
The study was approved by the Institutional Review Board (IRB) of Cleveland Clinic. 
Semen samples were used from 15 controls with proven fertility and 293 infertile men 
referred to our andrology laboratory from August 2015 through October 2016. The 
infertile men attending our male infertility clinic had confirmed male factor infertility. All 
patients were evaluated by a male infertility specialist. All infertile patients were seeking 
treatment for male factor infertility (idiopathic infertility, varicoceles, infection and other 
known aetiologies). Patients with infection, azoospermia, severe oligozoospermia (<1 × 106 
sperm/ml) or retrograde ejaculate were not included in the study. None of these patients 
were obese or had a history of chemotherapy or radiation. The female partners of these 
patients underwent a complete gynaecological investigation and were found to be healthy. 
 
2.2 | Study design 
After liquefaction, sperm count, motility, morphology and static oxidation–reduction 
potential (ORP) were determined in patients with adequate sperm counts. Semen samples 
were then categorised as oligozoospermic (OZ), asthenozoospermic (AZ) and 
teratozoospermic (TZ) according to the standard procedures described in 5th edition of 
2010 WHO guidelines [14] with the relevant cut-off values (OZ: sperm count <15 × 106/ml; 
AZ: total motility: <40%; TZ: normal sperm morphology: <4%). Subjects not falling into these 
categories were categorised as normozoospermic (NZ). These categories were compared with 
the two common categories “control” and “patient.” 
 
2.3 | Semen analysis 
Following liquefaction, a manual semen analysis was performed according to World Health 
Organization, 2010 guidelines to determine sperm concentration and motility. Five 
microlitres of the sample was used for manual evaluation of motility using a MicroCell 
counting chamber (Vitrolife, San Diego, CA) with phase contrast optics set at ×20 
magnification (Agarwal et al., 2015). 
 
2.4 | Measurement of white blood cells 
Samples with a high concentration of round cells (>5 per high power field) were examined 
for the presence of white blood cells, especially the granulocytes, by the peroxidase (Endtz) 
test (World Health Organization, 2010). To conduct the Endtz test, a 20-μl well-mixed 
aliquot of the semen sample was mixed with one volume of PBS and 2 volumes of working 
Endtz solution in an amber coloured Eppendorf tube. After 5 min, a drop of the aliquot was 
placed on a Makler chamber and examined for the presence of dark brown cells under an ×10 
bright field objective. Leukocytospermia was defined as the presence of >1 × 106 WBC/ml 






2.5 | Measurement of oxidation–reduction potential (ORP) 
Immediately after semen liquefaction, ORP was evaluated using the MiOXSYS Analyzer 
(Aytu BioScience Inc., Englewood, CO) according to the method described previously 
(Agarwal, Roychoudhury, Bjugstad, & Cho, 2016). In brief, 30 μl of liquefied semen was 
applied to the MiOXSYS  Sensor  at room temperature  and measured  in triplicate. 
 
The test starts when the sample fills the reference electrode, and the electrochemical circuit is 
completed. After a short period, the ORP values are displayed in millivolts (mV) on the 
screen. Average values were recorded and normalised to sperm concentration to control 
for differences in cell numbers. Thus, data are presented as mV/106 sperm/ml. The 
MiOXSYS System measures static ORP which provides a “snapshot” of the current balance of 
the redox system. A higher ORP level indicates an imbalance in the activity of all available 
oxidants relative to all available antioxidants in the seminal ejaculate and indicates a state of 
OS. 
 
2.6 | Statistical analysis 
Statistical analyses were carried out using the MedCalc Statistical Software, V. 17.1, 
[MedCalc Software bvba, Ostend, Belgium; https:// www.medcalc.org; 2017]. After checking 
for normal distribution of data with the Chi-squared test, the nonparametric tests, 
Spearman rank correlations, Mann–Whitney test and Jonckheere–Terpstra trend test were 
employed. In addition, Fisher’s exact test and a receiver operating characteristic (ROC) curve 
analyses with subsequent Hanley and McNeil method for ROC comparison were used to 
further analyse the data. A p-value of p < .05 was considered significant. 
 
3  |  RESULTS 
Summary statistics for all parameters taken are shown in Table 1. None of our controls 
presented with leukocytospermia. Among the patients, the incidence of leukocytosperrmia 
was 12.3% (36/293). Of these, 7.2% (21/293) had Endtz >1 × 106 WBC/ml; 3.1% (9/293) 
>1 but <2 × 106 WBC/ml; and 1.7% (6/293) presented with Endtz >5 × 106 WBC/ml 
presented with leukocytospermia. Of the 293 patients, only 38 (13%) were identified with 
clinical varicocele (38/293). A total of 308 subjects were enrolled in the study but due to low 
sperm concentration, not all subjects had motility, morphology and ORP performed. 
According to WHO criteria, 25.6% (75/293) of the patients were categorised as 
“normozoospermic” compared to 53.3% (8/15) among the fertile controls. 
 
Semen parameters and ORP for OZ, AZ and TZ as well as “patients” and “controls” are 
shown in Table 2. Direct comparison of the different subject groups “control,” “patient” and 
normozoospermia (NZ) revealed that except for ORP (p = .2087), “patients” and “controls” 
differed significantly (p < .05) for all parameters tested (Table 2). Generally, a trend for lower 
ORP values in subjects with higher sperm concentrations was found applying the 
Jonckheere–Terpstra trend test (p < .0001). For the groups “patient” and NZ, significant 




.0114) compared to the NZ group. No differences were seen in semen parameters between 
these two groups (Table 2). 
 
Comparisons between the patient and oligozoospermic (OZ) group  and  asthenozoospermic  
(AZ)  samples  revealed  significant differences (p < .0032). For the teratozoospermic group 
(TZ), these differences were only significant for motility (p = .0473) and morphology (p < 
.0001). As expected, ORP was highly significant (p < .0001) and negatively correlated with 
sperm concentration (r = -0.840), motility (r = -0.429) and weakly correlated with normal 









ROC curve analyses for the categories “patient”/”controls” revealed areas under the curve 
(AUC) for concentration (0.714; p < .0001), motility (0.752; p < .0001) and morphology 
(0.776; p < .0001) respectively. In contrast, ORP values for AUC were borderline significant 
between control and patients group (0.596; p = .0400). The highest predictive power to 
distinguish between “patient” and “control” was for morphology (Table 3). However, if the 
classification is made for any two abnormalities (low sperm count [OZ], low motility [AZ], 
poor morphology [TZ] or non-specified) (Figure 1, Table 3), the ROC curve and the prediction 
of the semen abnormality became highly significant (p < .0001). ORP had high predictive 
power for OZ patients (AUC = 0.919) (Table 3). Comparing the OAT and the non-OAT group, 
ORP the AUC and thus the predictive power of the test was not significantly different from 
those AUC’s for motility and normal sperm morphology. Only the AUC for the sperm 
concentration (0.920) was significantly higher (p = .0078) that that for ORP (0.822) (Table 3). 
 
4  |  DISCUSSION 
Many clinicians continue to rely on conventional semen parameters as a surrogate measure of 
a man’s ability to father a child (Esteves, 2010). However, assessing male fertility potential 
based on semen analysis results is inaccurate due to (i) large inter- and intra-operator 
variation in conventional semen analysis as well as a large overlap in semen parameters 
reported between fertile and infertile men (Agarwal et al., 2006); (ii) semen characteristics 
that discriminate between infertile and fertile men are not well defined, and the end results 
fall within the accepted reference ranges in up to 40% of infertile men (Agarwal et al., 2006; 
Guzick et al., 2001; van der Steeg et al., 2011). This is because conventional semen analysis 
does not assess the changes occurring as a result of oxidative stress or DNA fragmentation 
(Duran, Morshedi, Taylor, & Oehninger, 2002; Esteves, 2010; 3) reference values in the 5th 
edition of WHO guidelines are derived from a population of fertile men that is not 
representative of the infertile population but rather of fertile men and the reference values 




fecundity (Esteves, 2010) and 4) the WHO reference values are not globally representative 
(Esteves, 2010; Papillon-Smith, Baker, Agbo, & Dahan, 2015). Almost 30% of the infertile 
men who are unable to father a biological child present with a normal male infertility workup 
with one or two semen analysis (Esteves & Agarwal, 2011). Therefore, supplementing 
conventional semen analysis with a reliable measure of sperm quality, such as oxidative 
stress, is recommended (Agarwal, Zini, & Sigman, 2013). 
 
Oxidative stress plays a central role in the pathogenesis of male infertility attributed to 
various aetiologies (Ko et al., 2014; Sharma & Agarwal, 1996). It is a result of an imbalance 
between the reactive oxygen species (ROS) present in the ejaculate and the ability of the 
available antioxidants to quench these oxidants. Thus, excessive amounts of ROS have 
negative effects on sperm proteins, lipids and also lead to DNA fragmentation. 
 
The direct measurement of ROS by chemiluminescence assay is the most widely utilised 
option with different methods being used (Agarwal et al., 2015; Agarwal, Roychoudhury et 
al., 2016), whereas measurement of antioxidant levels or activities using the TAC assay are 







Previously, we used ROS levels to compare semen parameters and pregnancy in fertile men and had 
established a pregnancy compared to infertile men (Agarwal, Sharma et al., 2014). Infertile men had 
consistently poor semen parameters that correlated negatively with ROS levels irrespective of the 
clinical diagnosis. Similarly, when fertile donors were compared with different combinations of 
oligozoospermia and teratozoospermia, the ROS cut-off in the control group was significantly 
lower with a higher sensitivity and specificity when compared to different combinations of 
oligozoospermia and teratozoospermia. A positive relationship was seen between poor semen 
parameters and elevated ROS levels suggesting an underlying mechanism in these infertile 





More recently, we demonstrated that the ORP measurement by the MiOXSYS system is an 
invaluable clinical tool that simplifies complex OS assays. Higher ORP values indicate an 
imbalance in the activity of oxidants relative to antioxidants. Using ORP as a measure of oxidative 
stress (Agarwal, Sharma et al., 2016; Agarwal et al., 2017), our data reinforce the impression that 
oxidative stress is related to poor semen quality (Agarwal, Mulgund et al., 2014; Agarwal, Tvrda et 
al., 2014; Ko et al., 2014; Sharma et al., 1999). ORP measured in semen samples from male 
partners of infertile couples suggests that ORP is significantly lower in those samples that 




In an earlier study examining ORP data from 218 normozoospermic men and 69 OAT 
patients, higher levels of oxidative stress were recorded in oligoasthenoteratozoospermic 
group (p < .0001) and confirmed by ORP (Agarwal, Gupta et al., 2016). Higher ORP values 
were recorded in these men than the normozoospermic men who had normal sperm 
concentration, motility and morphology are supported by previous finding by Cavallini 
(2006). 
 
In an earlier study, an ORP cut-off value of 1.36 mV/106 sperm/ml was capable of predicting 
abnormality in semen quality with a sensitivity of 69.6%, a specificity of 83.1%, positive 
predictive value of 85.3% and a negative predictive value (NPV) of 65.9%. The accuracy of the 
test was 75.2% (AUC = 0.770). Negative correlations were reported in this study with sperm 
concentration, total sperm count, motility and morphology. Furthermore, the intra-observer 
and inter-observer reliability of ORP were very strong (correlations > 0.97%), suggesting that 
ORP testing can be clinically useful in identifying OS in men at risk of infertility that would 





In the present study, an larger number of subjects were enroled and examined for sperm 
concentration, motility, normal sperm morphology and ORP. The subjects were categorised 
as normozoospermic, oligozoospermic, asthenozoospermic, teratozoospermic or 
oliogoasthenoteratozoospermic. As expected, significant differences in semen parameters 
between the control and patient group were found. The distribution of leukocytospermia 
among the patients of 12.2% is similar (12%–19%) to that reported in the literature (Henkel 
et al., 2005; Sharma & Agarwal, 1996; Tremellen, 2008; World Health Organization, 2010). 
More importantly, the ORP levels were also significantly higher in all subgroups (when 
compared with the normozoospermic group (Table 2). ORP was able to distinguish between 
the patient and normozoospermic group (p < .0001), even when a patient presented with 
normal semen parameters (NZ). 
 
When the subjects were grouped based on semen parameters into oligozoospermic versus 
non-oligozoospermic, asthenozoospermic versus non-asthenozoospermic or 
teratozoospermic versus nonteratozoospermic; both sperm parameters and ORP were 
significantly different (p < .0001) (Table 3). 
 
A similar trend in significant differences in ROC parameters was seen between the 
oligoasthenoteratozoospermic versus non-oligoasthenoteratozoospermic group for both 
sperm parameters and ORP. Semen samples from oligoasthenoteratozoospermic (OAT) 
patients have higher levels of isoprostane (a by-product of arachidonic acid peroxidation), 
lower levels of catalase and have lower TAC levels and may contribute to the elevated ORP 
(Khosrowbeygi & Zarghami, 2007). 
 
To further establish the clinical utility of ORP, we examined the sensitivity and specificity of 
ORP in control and patients as well as in semen samples with at least 2 semen abnormalities 
(Table 3; Figure 1). The AUC was significantly higher when the ROC curve was calculated for 
ORP in patients with oligozoospermia or two abnormal semen parameters compared to one 
abnormal semen parameters only. 
 
For any diagnostic test to be considered valid for clinical use, it should combine high 
sensitivity, specificity, and positive and negative predictive values. When a given test has a 
high sensitivity, it will correctly identify subjects with the condition of interest, that is 
infertility as in this case. In contrast, highly specific tests correctly identify subjects who do 
not have this condition of interest. Although predictive values are influenced by sensitivity 
and specificity, they depend on the prevalence of the condition of interest in the general 
population. 
 
The classification of ejaculates according to the WHO criteria “normozoospermia,” 
“asthenozoospermia,” “oligozoospermia,” “teratozoospermia” etc. as well as the classification 
into “patient” and “donor” is standard practice in clinic and research and is regularly used to 
distinguish between different subjects. Therefore, it is important to notice that only about 
half of the “fertile” donors could be classified as being normozoospermic. For the overall 




including sperm count, motility and normal sperm morphology in a clinical laboratory in an 
andrology unit or even in the embryology laboratory just before an assisted reproduction 
procedure, carrying out these tests is time-consuming and costly. If one calculates the actual 
cost (consumables and technical charges only as the billing charges for these tests could vary 
greatly between the providers) for a routine semen analysis with sperm count, motility and 
normal morphology (World Health Organization, 2010) is about $35.00, the cost to measure 
ORP is approximately $10.00 or one-third the cost for a normal semen analysis. More 
importantly for the patient, measurement of ORP takes only about 5 min and can therefore be 
taken while the patient is still visiting the specialist. Results can therefore be discussed 
immediately without the need for a second visit. Hence, determination of ORP is easy, quick 
and cost-effective, with good predictive power, and the test can be of assistance to guide the 
clinician and embryologist in their decisions. 
 
In a recent publication examining the relationship between ORP and semen quality as well 
as examining the changes in sperm parameters over time, at a cut-off of 1.57 mV/106 sperm, 
we found high sensitivity of 70.4% and specificity of 88.1% with a PPV of 95.5%, 
irrespective of their clinical diagnoses (Agarwal & Wang, 2017). At a cut-off of 2.59 mV/106 
sperm, ORP could differentiate controls, from infertile men suffering from oligozoospermia. 
This finding also points out to the fact that OS may be a primary mechanism in reducing sperm 
concentration in these patients. 
 
Our results demonstrate a number of important findings; (I) semen parameters and ORP both 
show significant differences in the ROC curves for AUC, sensitivity, specificity and 
predictive value especially when abnormal semen parameters (concentration, motility or 
morphology are compared to those with normal semen parameters or when subjects with 
two of the three abnormal semen parameters are compared); (ii) semen analysis requires 
highly trained staff, is costly and does not test for sperm function characteristics such as OS; 
(iii) ORP represents a direct measure of oxidative stress that is objective, repeatable and can 
be performed in less than 4 min without costly equipment or highly trained staff. Therefore, 
ORP represents an effective and more cost-efficient measure of OS in comparison with ROS, 
TAC and MDA assays. The test can be performed while the patient is still with the 
physician, and therefore, the result can be discussed immediately. This saves the patient 
from returning for a second time to discuss the test results. 
 
The large variation in the distribution of ORP levels between the controls and the different 
subgroups signifies the importance of OS in the pathophysiology of male infertility. When 
controls with unproven fertility were included in the control group analysis, no differences 
were seen in the ROC curve. Therefore, it is important to determine the fertility status in 
patients and controls as not every control might be fertile and not every patient infertile 
based only on the semen parameters. This is even valid for the distinction of subjects 
according to WHO criteria. Men with infertility had a significantly higher ORP value in all 
these subgroups than men in the control group. Assessing ORP in men seeking fertility 
should help the clinician identify an important sperm function characteristic that would 




also be used to monitor the effectiveness of treatment for oxidative stress. The main 
limitation of the present study was that the samples were taken from a male infertility clinic, 
and therefore, we are unable to determine further outcome studies associated with clinical 
pregnancy and live birth outcomes. Another limitation of our study was the small number of 
fertile controls. However, our analysis shows statistical significance despite the small size of 
the control group. 
 
In conclusion, our results demonstrate that measurement of ORP is an accurate and rapid 
test of semen quality that can be used routinely in clinical practice. The test is not a 
replacement for semen analysis, rather it can be used in conjunction with a routine semen 
analysis to help evaluate oxidative stress induced male infertility. Due to the rapid 
turnaround time and ease of use, it can be potentially used as a stand-alone sperm function 
test to help rule in male infertility cases associated with oxidative stress when semen 
analysis is not readily available. 
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